Sign up
Pharma Capital

Faron Pharma welcomes latest Clever-1 data

Clever-1 is a cell surface receptor shown to control cell-mediated immunity
Faron Pharma is developing a treatment that could help the human body's immune system tackle cancer

Research to be published in a leading scientific journal reveals how Clever-1 is important in the process of humoral immunity.

Clever-1 is a cell surface receptor shown to control a certain form of immunity.

READ: Faron Pharmaceuticals to file clinical trial application for Clevegen after successful study

Data carried by Frontiers in Immunology suggest that disrupting the function of Clever-1 probably does not lead to the suppression of antibody production.

Rather it could improve humoral immune responses against tumour antigens and during vaccinations.

Faron Pharma (LON:FARN) is developing a fully human anti-Clever-1 antibody called Clevegen.

It said the efficacy of anti-Clever-1 antibodies in experimental models supported the development of its potential cancer immunotherapy, which is due to enter the clinic later this year.

Faron chief executive, Dr Markku Jalkanen, said: "This is a fascinating finding and builds up further evidence for the importance to control Clever-1 function in conditions where active immune suppression can cause disease or worsen disease development.

“It provides further scientific rationale for our Vaccination Response Enhancement Technology programme, which is currently under early investigation with Clevegen."

View full FARN profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.